Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 433 Carcinoma, Non-Small-Cell Lung 372 Neoplasms 326 Prostatic Neoplasms 244 Leukemia, Myeloid, Acute 231 Multiple Myeloma 230 Neoplasm Metastasis 215 Melanoma 202 Lung Neoplasms 178 Leukemia 172 Lymphoma 170 Colorectal Neoplasms 157 Pancreatic Neoplasms 151 Lymphoma, Non-Hodgkin 150 Recurrence 149 Ovarian Neoplasms 146 Leukemia, Lymphocytic, Chronic, B-Cell 134 Precursor Cell Lymphoblastic Leukemia-Lymphoma 131 Myelodysplastic Syndromes 121 Carcinoma, Renal Cell 121 Lymphoma, Large B-Cell, Diffuse 111 Lymphoma, Follicular 108 Brain Neoplasms 101 Squamous Cell Carcinoma of Head and Neck 96 Head and Neck Neoplasms 96 Glioblastoma 92 Urinary Bladder Neoplasms 88 Carcinoma, Hepatocellular 80 Hodgkin Disease 73 Colonic Neoplasms 73

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Has results × rrCLL × Clear all

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡